The Addario Lung Cancer Medical Institute
ALCMI is a 501(c)(3) nonprofit research consortium that accelerates investigator-initiated lung cancer clinical trials by providing funding, staffing, and a 2,000+ biospecimen bank to researchers across 24-56 partner oncology institutions.
- Company typePrivate
- Founded2008
- HeadquartersSan Carlos, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
What The Addario Lung Cancer Medical Institute does
The Addario Lung Cancer Medical Institute (ALCMI) is a 501(c)(3) nonprofit research organization founded in 2008 and headquartered in San Carlos, California, whose stated mission is to make lung cancer a survivable disease. ALCMI operates as a research consortium that accelerates investigator-initiated clinical trials by providing funding, staffing, and operational expertise to oncology researchers at 24-56 partner institutions, including Dana-Farber Cancer Institute, Harvard Medical School, Massachusetts General Hospital, Gustave Roussy, and multiple University of California schools. Its technology platform centers on a remote, decentralized observational biomarker trial model, exemplified by the SPACEWALK study using plasma cell-free DNA genotyping for ALK resistance mechanism research, and on a biospecimen bank containing more than 2,000 specimens.
ALCMI concentrates its research across five focus areas: Young Lung Cancer, Inheritable Disease, Resistance Mechanisms, Collaboration, and Specimen Research. Current flagship work includes the INHERIT (Investigating Hereditary Risk in Thoracic Cancers) trial, co-led with Dana-Farber and the GO2 for Lung Cancer advocacy organization. To date the institute has completed 23 clinical trials enrolling 1,754 participants and has produced peer-reviewed publications including germline EGFR studies in the Journal of Clinical Oncology, generating 13,659 cumulative citations and downloads.
The business model is donation- and sponsorship-driven: ALCMI is funded by individual donors, foundations, and commercial sponsors and provides research services, funding, and staffing to academic investigators at no cost to them. There are no product sales or service fees; the organization does not operate traditional pricing or commercial distribution channels. Marketing and outreach are conducted through a website, social media (LinkedIn, Twitter/X, Facebook, Bluesky), email newsletters, press releases, and peer-reviewed publication, with research outputs disseminated through academic journals and direct collaboration with consortium partners.
The Addario Lung Cancer Medical Institute firmographics
Firmographics- Name
- The Addario Lung Cancer Medical Institute
- Legal name
- Addario Lung Cancer Medical Institute
- Website
- https://alcmi.net
- Company type
- Private
- Founded year
- 2008
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- ALCMI is a 501(c)(3) nonprofit research consortium that accelerates investigator-initiated lung cancer clinical trials by providing funding, staffing, and a 2,000+ biospecimen bank to researchers across 24-56 partner oncology institutions.
- Ownership category
- akta.pro rank
The Addario Lung Cancer Medical Institute industry classification
Industry- Product category
- Clinical Research Services
- NAICS
- Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro industry
- Site Data Management Support (EDC/Source/SDV Readiness)Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Clinical Trial Services & Site Management (SMO)Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF)Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D)Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
Keywords
Where The Addario Lung Cancer Medical Institute is headquartered
LocationHeadquarters
- HQ city
- San Carlos
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
The Addario Lung Cancer Medical Institute business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Others
Revenue model
- Donations and Charitable Contributions: As a 501c(3) public charity (Tax ID 26-1721868), ALCMI receives donations from individual donors, foundations, and organizations to fund lung cancer research and clinical trials.
- Sponsorship Funding: Commercial sponsors and organizations sponsor ALCMI's research programs and clinical trials, providing financial support in exchange for research outcomes and collaboration.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels8 records
The Addario Lung Cancer Medical Institute product offering
Product offeringCore offering
ALCMI is a 501c(3) nonprofit research institute that accelerates investigator-initiated lung cancer clinical trials by providing funding, dedicated staff, and expert teams to oncology researchers. It operates a consortium of 24+ premier oncology research institutions and maintains a biospecimen bank with more than 2,000 specimens, while pioneering remote decentralized observational biomarker trials and plasma cell-free DNA genotyping for resistance mechanism research.
Product overview
The Addario Lung Cancer Medical Institute (ALCMI) is a nonprofit organization that accelerates investigator-initiated lung cancer clinical trials. As a 501c(3) public charity, ALCMI operates as a unified platform offering clinical trial coordination services, funding, staffing, and expert guidance. The organization's integrated offerings include a biospecimen bank with over 2,000 specimens, the INHERIT Trial focused on hereditary lung cancer risk, a researcher portal for trial concept submission, and peer-reviewed publications. ALCMI concentrates research in five focus areas: Young Lung Cancer, Inheritable Disease, Resistance Mechanisms, Collaboration, and Specimen Research. The organization partners with 56 institutions including Dana-Farber Cancer Institute, Gustave Roussy, and other premier oncology research organizations to conduct clinical trials that advance new therapeutics, diagnostics, and understanding of lung cancer risk factors and resistance mechanisms.
Differentiator
Problem solved
Functional benefit
Products and services
- Clinical Trial Coordination Services
Quantifiable outcome
- 23 clinical trials completed with 1,754 trial participants
- +1 more outcomes
Companies that use The Addario Lung Cancer Medical Institute
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles3 records
The Addario Lung Cancer Medical Institute technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
The Addario Lung Cancer Medical Institute partnerships and signals
Strategic signalPartnerships
26 partnerships are on record, tiered core.
- Dana-Farber Cancer InstitutecoreMajor consortium partner collaborating on multiple studies including the INHERIT trial investigating hereditary lung cancer risk. Dr. Biagio Ricciuti from Dana-Farber provides testimonial on the value of collaboration with ALCMI for resistance mechanism research.
- GO2 for Lung CancercorePatient advocacy partner co-leading the INHERIT (Investigating Hereditary Risk in Thoracic Cancers) study alongside Dana-Farber Cancer Institute, focusing on genetic and environmental risk factors for lung cancer.
- Harvard Medical SchoolcoreConsortium partner providing research collaboration and expertise in oncology research.
- Massachusetts General HospitalcoreConsortium partner contributing to lung cancer research and clinical trials.
- Gustave RoussycoreEuropean consortium partner, one of the world's leading cancer research centers based in France, contributing to international research collaboration.
- City of HopecoreConsortium partner providing research collaboration in cancer care and research.
- The Ohio State UniversitycoreConsortium partner contributing research expertise and resources to ALCMI trials.
- Vanderbilt University Medical CentercoreConsortium partner participating in lung cancer research collaboration.
- Washington University - St. LouiscoreConsortium partner contributing to research and clinical trial activities.
- NYU School of MedicinecoreConsortium partner in the ALCMI research network.
- UC-San FranciscocoreConsortium partner contributing research expertise to ALCMI.
- UC-San DiegocoreConsortium partner participating in lung cancer research studies.
- UC-DaviscoreConsortium partner contributing to ALCMI research activities.
- USCcoreConsortium partner providing research collaboration.
- The University of ManchestercoreInternational consortium partner from the UK contributing to global research collaboration.
- University of TorinocoreEuropean consortium partner contributing to international research efforts.
- Rush University Medical CentercoreConsortium partner participating in research network.
- MemorialCarecoreConsortium partner contributing to research and clinical trials.
- MontefiorecoreConsortium partner in the ALCMI network.
- Northside HospitalcoreConsortium partner contributing to cancer research.
- Palo Alto Medical FoundationcoreConsortium partner providing research collaboration.
- El Camino HealthcoreConsortium partner contributing to research network.
- Dignity HealthcoreConsortium partner participating in ALCMI research.
- Baptist MemorialcoreConsortium partner contributing to research activities.
- Boca Raton Regional HospitalcoreConsortium partner in the ALCMI research network.
- St. Louis Cancer CarecoreConsortium partner contributing to cancer research.
Scale indicators6 records
Recent moves6 records
Expansion highlights5 records
The Addario Lung Cancer Medical Institute competitors and assessment
Company assessmentBroad incumbents
- Memorial Sloan Kettering Cancer Center: MSKCC runs investigator-initiated thoracic oncology trials, maintains large biospecimen resources, and publishes in top oncology journals. It is a peer in terms of clinical trial output and biomarker research, though as a comprehensive cancer center rather than a disease-specific nonprofit consortium.
- Prevent Cancer Foundation: Prevent Cancer Foundation funds and convenes cancer prevention and early-detection research across multiple cancer types. Its research grant and consortium model is comparable, but with a prevention focus and broader scope than ALCMI.
- Cancer Research Institute: Cancer Research Institute is a long-established nonprofit funding immunology and immuno-oncology research across cancer types. Its clinical trial accelerator program is structurally analogous to ALCMI's consortium model, but at much broader scope.
Direct peers
- Stand Up To Cancer: Stand Up To Cancer funds collaborative, multi-institutional translational cancer research including lung cancer-specific "Dream Teams." Like ALCMI, it pools funding across premier cancer centers to accelerate investigator-initiated trials.
- GO2 for Lung Cancer: GO2 is a patient advocacy and support organization for the lung cancer community and is already listed as a core partner of ALCMI on the INHERIT study. It is comparable as a lung cancer-focused nonprofit doing research, education, and patient navigation.
- Lung Cancer Research Foundation: LCRF is a nonprofit that funds lung cancer research grants and runs educational programs, mirroring ALCMI's nonprofit research-funding, patient-outreach, and scientific publications portfolio.
- ECOG-ACRIN Cancer Research Group: ECOG-ACRIN is an NCI-sponsored clinical trial consortium that designs and runs multi-institution oncology trials, including lung cancer studies. Comparable to ALCMI as a multi-institution clinical trial operator, though at much larger scale and with NCI backing.
- LUNGevity Foundation: LUNGevity is one of the largest lung cancer-focused nonprofit funders, supporting research grants, education, and patient advocacy. It directly parallels ALCMI's lung cancer research funding and patient/community engagement model.
- International Association for the Study of Lung Cancer (IASLC): IASLC is the leading global professional society dedicated to the study of lung cancer, funding research, publishing guidelines, and convening researchers worldwide. Comparable in mission and global research network to ALCMI.
Emerging players
- Translational Genomics Research Institute (TGen): TGen is a nonprofit research institute that conducts genomic and precision-medicine clinical research, including lung cancer. Comparable to ALCMI in combining biospecimen, genomics, and clinical trial capabilities for translational oncology.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights7 records
Customer concentration
The Addario Lung Cancer Medical Institute social profiles
Digital presenceThe Addario Lung Cancer Medical Institute compliance and trust
Trust signalCompliance1 record
The Addario Lung Cancer Medical Institute financial estimates
Financial estimateRevenue estimate
Valuation estimate
The Addario Lung Cancer Medical Institute leadership team
Management profileNumber of profiles
The Addario Lung Cancer Medical Institute funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
The Addario Lung Cancer Medical Institute M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about The Addario Lung Cancer Medical Institute
What does The Addario Lung Cancer Medical Institute do?
ALCMI is a 501c(3) nonprofit research institute that accelerates investigator-initiated lung cancer clinical trials by providing funding, dedicated staff, and expert teams to oncology researchers. It operates a consortium of 24+ premier oncology research institutions and maintains a biospecimen bank with more than 2,000 specimens, while pioneering remote decentralized observational biomarker trials and plasma cell-free DNA genotyping for resistance mechanism research.
Is The Addario Lung Cancer Medical Institute a public or private company?
The Addario Lung Cancer Medical Institute is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was The Addario Lung Cancer Medical Institute founded?
The Addario Lung Cancer Medical Institute was founded in 2008. It employs 1 to 10 people.
Where is The Addario Lung Cancer Medical Institute based?
The Addario Lung Cancer Medical Institute is headquartered in San Carlos, United States, in the North America region.
How does The Addario Lung Cancer Medical Institute make money?
Two revenue lines are on record. Donations and Charitable Contributions are the primary driver. The others are sponsorship Funding.
Who are The Addario Lung Cancer Medical Institute's main competitors?
Broad incumbents on record are Memorial Sloan Kettering Cancer Center, Prevent Cancer Foundation and Cancer Research Institute. Direct peers are Stand Up To Cancer, GO2 for Lung Cancer, Lung Cancer Research Foundation, ECOG-ACRIN Cancer Research Group, LUNGevity Foundation and International Association for the Study of Lung Cancer (IASLC). Translational Genomics Research Institute (TGen) is listed as an emerging player.
Does The Addario Lung Cancer Medical Institute have an API?
No public API is recorded for The Addario Lung Cancer Medical Institute.
What industry is The Addario Lung Cancer Medical Institute in?
The Addario Lung Cancer Medical Institute's product category is Clinical Research Services. Its primary akta.pro industry code is HLAGACAL, Site Data Management Support (EDC/Source/SDV Readiness), with a secondary code of HLAGAJAM, Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF). Its NAICS code is 54171 and its SIC code is 8731.